Total Payments
$443,331
2024 Payments
$1,645
Companies
6
Transactions
103
Medicare Patients
7,639
Medicare Billing
$895,877
Payment Breakdown by Category
Consulting$439,445 (99.1%)
Research$3,315 (0.7%)
Food & Beverage$570.59 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $439,445 | 90 | 99.1% |
| Unspecified | $3,315 | 3 | 0.7% |
| Food and Beverage | $570.59 | 10 | 0.1% |
Payments by Type
General
$440,016
100 transactions
Research
$3,315
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $439,445 | 90 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $3,315 | 3 | $0 (2024) |
| DePuy Synthes Sales Inc. | $236.56 | 5 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $121.88 | 2 | $0 (2017) |
| Lilly USA, LLC | $118.83 | 2 | $0 (2017) |
| GE HealthCare | $93.32 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,645 | 2 | E.R. Squibb & Sons, L.L.C. ($1,620) |
| 2023 | $1,578 | 3 | E.R. Squibb & Sons, L.L.C. ($1,515) |
| 2022 | $421.89 | 4 | E.R. Squibb & Sons, L.L.C. ($180.00) |
| 2021 | $315,610 | 48 | Merck Sharp & Dohme Corporation ($315,610) |
| 2020 | $122,830 | 38 | Merck Sharp & Dohme Corporation ($122,830) |
| 2019 | $1,005 | 4 | Merck Sharp & Dohme Corporation ($1,005) |
| 2017 | $240.71 | 4 | Bayer HealthCare Pharmaceuticals Inc. ($121.88) |
All Payment Transactions
103 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/07/2024 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $1,620.00 | Research |
| Study: Phase IIA CTLA4 NF Randomized chemo combo study in mCRPC - A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer | ||||||
| 01/08/2024 | DePuy Synthes Sales Inc. | ALTALYNE (Device) | Food and Beverage | In-kind items and services | $25.07 | General |
| Category: Spine | ||||||
| 08/02/2023 | DePuy Synthes Sales Inc. | FIBERGRAFT BG MORSELS (Device) | Food and Beverage | In-kind items and services | $30.12 | General |
| Category: Spine | ||||||
| 04/12/2023 | DePuy Synthes Sales Inc. | EXPEDIUM (Device) | Food and Beverage | In-kind items and services | $32.80 | General |
| Category: Spine | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $1,515.00 | Research |
| Study: Phase IIA CTLA4 NF Randomized chemo combo study in mCRPC - A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer | ||||||
| 10/12/2022 | DePuy Synthes Sales Inc. | EXPEDIUM (Device) | Food and Beverage | In-kind items and services | $36.23 | General |
| Category: Spine | ||||||
| 09/08/2022 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $180.00 | Research |
| Study: Phase IIA CTLA4 NF Randomized chemo combo study in mCRPC - A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer | ||||||
| 08/23/2022 | DePuy Synthes Sales Inc. | EXPEDIUM (Device) | Food and Beverage | In-kind items and services | $112.34 | General |
| Category: Spine | ||||||
| 07/12/2022 | GE HealthCare | — | Food and Beverage | Cash or cash equivalent | $93.32 | General |
| 12/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $11,770.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $7,290.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $5,220.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,340.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $8,640.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $8,550.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $4,860.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $540.00 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $13,900.00 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $7,380.00 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $6,480.00 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $5,850.00 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $7,470.00 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $7,010.00 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $4,140.00 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,970.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase IIA CTLA4 NF Randomized chemo combo study in mCRPC - A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer | E.R. Squibb & Sons, L.L.C. | $3,315 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 36 | 1,736 | 4,135 | $1.1M | $193,699 |
| 2022 | 40 | 1,781 | 4,167 | $959,556 | $184,638 |
| 2021 | 42 | 2,084 | 5,798 | $1.4M | $263,523 |
| 2020 | 42 | 2,038 | 5,392 | $1.3M | $254,017 |
Total Patients
7,639
Total Services
19,492
Medicare Billing
$895,877
Procedure Codes
206
All Medicare Procedures & Services
206 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 57 | 63 | $469,161 | $94,468 | 20.1% |
| 77067 | Screening mammography | Office | 2023 | 116 | 116 | $90,828 | $16,747 | 18.4% |
| 77063 | Screening 3d breast mammography | Office | 2023 | 116 | 116 | $32,944 | $6,735 | 20.4% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 62 | 70 | $8,085 | $6,117 | 75.7% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Facility | 2023 | 62 | 66 | $38,940 | $5,902 | 15.2% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 14 | 15 | $23,088 | $4,312 | 18.7% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2023 | 55 | 55 | $24,915 | $3,702 | 14.9% |
| 72148 | Mri scan of lower spinal canal without contrast | Office | 2023 | 23 | 23 | $25,870 | $3,373 | 13.0% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 29 | 29 | $24,856 | $3,221 | 13.0% |
| 70450 | Ct scan head or brain without contrast | Facility | 2023 | 95 | 98 | $20,874 | $3,169 | 15.2% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 46 | 46 | $17,894 | $2,886 | 16.1% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 31 | 31 | $18,165 | $2,810 | 15.5% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 62 | 62 | $20,150 | $2,648 | 13.1% |
| 76700 | Complete ultrasound scan of abdomen | Office | 2023 | 26 | 26 | $15,983 | $2,624 | 16.4% |
| 73721 | Mri scan of leg joint without contrast | Office | 2023 | 16 | 16 | $17,592 | $2,478 | 14.1% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 14 | 14 | $13,503 | $2,411 | 17.9% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 80 | 80 | $11,380 | $2,326 | 20.4% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 22 | 22 | $12,780 | $2,147 | 16.8% |
| 93971 | Ultrasound study of one arm or leg veins with compression and maneuvers | Office | 2023 | 18 | 18 | $11,349 | $1,844 | 16.2% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Office | 2023 | 11 | 11 | $11,337 | $1,795 | 15.8% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Facility | 2023 | 24 | 24 | $10,392 | $1,656 | 15.9% |
| 71250 | Ct scan of chest without contrast | Facility | 2023 | 36 | 36 | $9,144 | $1,426 | 15.6% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Facility | 2023 | 47 | 47 | $8,601 | $1,391 | 16.2% |
| 77065 | Diagnostic mammography of 1 breast | Office | 2023 | 13 | 13 | $9,906 | $1,355 | 13.7% |
| 76830 | Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | Office | 2023 | 11 | 11 | $6,840 | $1,199 | 17.5% |
About Dr. John Ghazi, M.D
Dr. John Ghazi, M.D is a Diagnostic Radiology healthcare provider based in Kendall Park, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548288905.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Ghazi, M.D has received a total of $443,331 in payments from pharmaceutical and medical device companies, with $1,645 received in 2024. These payments were reported across 103 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($439,445).
As a Medicare-enrolled provider, Ghazi has provided services to 7,639 Medicare beneficiaries, totaling 19,492 services with total Medicare billing of $895,877. Data is available for 4 years (2020–2023), covering 206 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location Kendall Park, NJ
- Active Since 07/17/2006
- Last Updated 08/16/2007
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1548288905
Products in Payments
- KEYTRUDA (Biological) $356,705
- MK-7339 (Drug) $30,285
- EXPEDIUM (Device) $181.37
- Xofigo (Drug) $121.88
- AMYVID (Drug) $118.83
- FIBERGRAFT BG MORSELS (Device) $30.12
- ALTALYNE (Device) $25.07
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Kendall Park
Dr. Eric Perlman, M.d, M.D
Diagnostic Radiology — Payments: $1.9M
Diagnostic Radiology $1.9M
Dr. Gregory Kaufmann, M.d, M.D
Diagnostic Radiology — Payments: $699,440
Diagnostic Radiology $699,440
Dr. Gerard Compito, M.d, M.D
Diagnostic Radiology — Payments: $422,308
Diagnostic Radiology $422,308
Dr. Robert Ford, M.d, M.D
Diagnostic Radiology — Payments: $240,605
Diagnostic Radiology $240,605
Dr. Samuel Greene, M.d, M.D
Diagnostic Radiology — Payments: $131,187
Diagnostic Radiology $131,187
Dr. Jonathan Lebowitz, M.d, M.D
Diagnostic Radiology — Payments: $9,174
Diagnostic Radiology $9,174